Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 74
Filter
1.
Neuroscience ; 329: 318-25, 2016 08 04.
Article in English | MEDLINE | ID: mdl-27208618

ABSTRACT

Chronic morphine treatment increases the levels of prohormone convertase 2 (PC2) in brain regions involved in nociception, tolerance and dependence. Thus, we tested if PC2 null mice exhibit altered morphine-induced antinociception, tolerance and dependence. PC2 null mice and their wild-type controls were tested for baseline hot plate latency, injected with morphine (1.25-10mg/kg) and tested for antinociception 30min later. For tolerance studies, mice were tested in the hot plate test before and 30min following morphine (5mg/kg) on day 1. Mice then received an additional dose so that the final dose of morphine was 10mg/kg on this day. On days 2-4, mice received additional doses of morphine (20, 40 and 80mg/kg on days 1, 2, 3, and 4, respectively). On day 5, mice were tested in the hot plate test before and 30min following morphine (5mg/kg). For withdrawal studies, mice were treated with the escalating doses of morphine (10, 20, 40 and 80mg/kg) for 4days, implanted with a morphine pellet on day 5 and 3 days later injected with naloxone (1mg/kg) and signs of withdrawal were recorded. Morphine dose-dependently induced antinociception and the magnitude of this response was greater in PC2 null mice. Tolerance to morphine was observed in wild-type mice and this phenomenon was blunted in PC2 null mice. Withdrawal signs were also reduced in PC2 null mice. Immunohistochemical studies showed up-regulation of the mu opioid receptor (MOP) protein expression in the periaqueductal gray area, ventral tegmental area, lateral hypothalamus, medial hypothalamus, nucleus accumbens, and somatosensory cortex in PC2 null mice. Likewise, naloxone specific binding was increased in the brains of these mice compared to their wild-type controls. The results suggest that the PC2-derived peptides may play a functional role in morphine-induced antinociception, tolerance and dependence. Alternatively, lack of opioid peptides led to up-regulation of the MOP and altered morphine-induced antinociception, tolerance and dependence.


Subject(s)
Analgesics, Opioid/pharmacology , Morphine Dependence/metabolism , Morphine/pharmacology , Nociceptive Pain/drug therapy , Proprotein Convertase 2/deficiency , Receptors, Opioid, mu/metabolism , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Dose-Response Relationship, Drug , Drug Tolerance/physiology , Male , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Morphine Dependence/pathology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Nociceptive Pain/metabolism , Proprotein Convertase 2/genetics , Substance Withdrawal Syndrome/metabolism , Substance Withdrawal Syndrome/pathology
2.
Int J Obes (Lond) ; 40(8): 1233-41, 2016 08.
Article in English | MEDLINE | ID: mdl-27102048

ABSTRACT

BACKGROUND: Increased adiposity in visceral depots is a crucial feature associated with glucocorticoid (GC) excess. The action of GCs in a target tissue is regulated by GC receptor (GR) and 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) coupled with hexose-6-phosphate dehydrogenase (H6pdh). Glycogen synthase kinase-3ß (GSK3ß) is known to be a crucial mediator of ligand-dependent gene transcription. We hypothesized that the major effects of corticosteroids on adipose fat accumulation are in part mediated by changes in GSK3ß and H6pdh. METHODS: We characterized the alterations of GSK3ß and GC metabolic enzymes, and determined the impact of GR antagonist mifepristone on obesity-related genes and the expression of H6pdh and 11ß-HSD1 in adipose tissue of mice exposed to excess GC as well as in in vitro studies using 3T3-L1 adipocytes treated with GCs. RESULTS: Corticosterone (CORT) exposure increased abdominal fat mass and induced expression of lipid synthase acetyl-CoA carboxylase and ATP-citrate lyase with activation of GSK3ß phosphorylation in abdominal adipose tissue of C57BL/6J mice. Increased pSer(9) GSK3ß was correlated with the induction of H6pdh and 11ß-HSD1. In addition, mifepristone treatment reversed the production of H6pdh and attenuated CORT-mediated production of 11ß-HSD1 and lipogenic gene expression with reduction of pSer(9) GSK3ß, thereby leading to improvement of phenotype of adiposity within adipose tissue in mice treated with excess GCs. Suppression of pSer(9) GSK3ß by mifepristone was accompanied by activation of pThr(308) Akt and blockade of CORT-induced adipogenic transcriptor C/EBPα and PPARγ. In addition, mifepristone also attenuated CORT-mediated activation of IRE1α/XBP1. In addition, reduction of H6pdh by shRNA showed comparable effects to mifepristone on attenuating CORT-induced expression of GC metabolic enzymes and improved lipid accumulation in vitro in 3T3-L1 adipocytes. CONCLUSION: These findings suggest that elevated adipose GSK3ß and H6pdh expression contribute to 11ß-HSD1 mediating hypercortisolism associated with visceral adiposity.


Subject(s)
Adipose Tissue/enzymology , Adiposity/drug effects , Carbohydrate Dehydrogenases/metabolism , Glucocorticoids/pharmacology , Glycogen Synthase Kinase 3 beta/metabolism , Adipocytes/enzymology , Adipocytes/metabolism , Adipogenesis/drug effects , Adiposity/genetics , Animals , Carbohydrate Dehydrogenases/biosynthesis , Disease Models, Animal , Glycogen Synthase Kinase 3 beta/biosynthesis , Hormone Antagonists/pharmacology , Intra-Abdominal Fat/drug effects , Male , Mice , Mice, Inbred C57BL , Mifepristone/pharmacology , Obesity, Abdominal/enzymology , Obesity, Abdominal/genetics , Obesity, Abdominal/metabolism , Receptors, Glucocorticoid/antagonists & inhibitors
3.
Horm Metab Res ; 47(4): 280-3, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25011019

ABSTRACT

Low vitamin D levels are associated with minority subjects, the metabolic syndrome, and inflammation. The effect of vitamin D supplementation on markers of inflammation has not been well studied. The aim of the study was to evaluate the effects of high doses of vitamin D supplementation for 1 year on serum biomarkers of inflammation in Latino and African-American subjects with pre-diabetes and hypovitaminosis D. Latino (n=69) and African-American (n=11) subjects who had both pre-diabetes and hypovitaminosis D with a mean age of 52.0 years, a BMI of 32.7 kg/m(2), and 70% of whom were females, were randomized to receive weekly doses (mean±SD) of vitamin D (85 300 IU±16 000) or placebo oil for 1 year. Serum levels of interleukin-6, tumor necrosis factor, highly sensitive C-reactive protein), plasminogen activator inhibitor 1, and insulin-like growth factor-1 were measured at baseline, 6, and 12 months. Serum 25-OH vitamin D levels of 22 ng/ml at baseline quickly rose to nearly 70 ng/ml in subjects receiving vitamin D and did not change in the placebo group. Two-way repeated measures ANOVA showed no differences between the 2 groups in any of the 5 selected parameters. High dose vitamin D supplementation for 1 year in minority subjects with pre-diabetes and hypovitaminosis D failed to affect serum biomarkers of inflammation.Clinical trial reg. no.: NCT00876928, clinicaltrials.gov.


Subject(s)
Black or African American , Hispanic or Latino , Inflammation/blood , Prediabetic State/blood , Vitamin D Deficiency/blood , Vitamin D/administration & dosage , Adult , Biomarkers/blood , Body Mass Index , C-Reactive Protein/analysis , Dietary Supplements , Female , Humans , Insulin-Like Growth Factor I/analysis , Interleukin-6/blood , Male , Middle Aged , Placebos , Plasminogen Activator Inhibitor 1/blood , Vitamin D/analogs & derivatives , Vitamin D/blood
4.
Horm Metab Res ; 46(8): 568-73, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24830635

ABSTRACT

Smoking is a major risk factor for diabetes and cardiovascular disease and may contribute to nonalcoholic fatty liver disease (NAFLD). The health risk associated with smoking is exaggerated by obesity and is the leading causes of morbidity and mortality worldwide. We recently demonstrated that combined treatment with nicotine and a high-fat diet (HFD) triggers greater oxidative stress, activates hepatocellular apoptosis, and exacerbates HFD-induced hepatic steatosis. Given that hepatocellular apoptosis plays a pivotal role in the pathogenesis of NAFLD, using this model of exacerbated hepatic steatosis, we elucidated the signal transduction pathways involved in HFD plus nicotine-induced liver cell death. Adult C57BL6 male mice were fed a normal chow diet or HFD with 60% of calories derived from fat and received twice daily IP injections of 0.75 mg/kg BW of nicotine or saline for 10 weeks. High-resolution light microscopy revealed markedly higher lipid accumulation in hepatocytes from mice received HFD plus nicotine, compared to mice on HFD alone. Addition of nicotine to HFD further resulted in an increase in the incidence of hepatocellular apoptosis and was associated with activation of caspase 2, induction of inducible nitric oxide synthase (iNOS), and perturbation of the BAX/BCL-2 ratio. Together, our data indicate the involvement of caspase 2 and iNOS-mediated apoptotic signaling in nicotine plus HFD-induced hepatocellular apoptosis. Targeting the caspase 2-mediated death pathway may have a protective role in development and progression of NAFLD.


Subject(s)
Apoptosis/drug effects , Caspase 2/metabolism , Diet, High-Fat , Hepatocytes/pathology , Nicotine/pharmacology , Nitric Oxide Synthase Type II/metabolism , Signal Transduction/drug effects , Animals , Blotting, Western , Fatty Liver/enzymology , Fatty Liver/pathology , Hepatocytes/drug effects , Hepatocytes/enzymology , Male , Mice, Inbred C57BL , Mice, Obese , Models, Biological
5.
Diabetologia ; 54(2): 440-50, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21052977

ABSTRACT

AIMS/HYPOTHESIS: Tissue-specific amplification of glucocorticoid action through 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) affects the development of the metabolic syndrome. Hexose-6-phosphate dehydrogenase (H6PDH) mediates intracellular NADPH availability for 11ß-HSD1 and depends on the glucose-6-phosphate transporter (G6PT). Little is known about the tissue-specific alterations of H6PDH and G6PT and their contributions to local glucocorticoid action in db/db mice. METHODS: We characterised the role of H6PDH and G6PT in pre-receptor metabolism of glucocorticoids by examining the production of the hepatic 11ß-HSD1-H6PDH-G6PT system in db/db mice. RESULTS: We observed that increased production of hepatic H6PDH in db/db mice was paralleled by upregulation of hepatic G6PT production and responded to elevated circulating levels of corticosterone. Treatment of db/db mice with the glucocorticoid antagonist RU486 markedly reduced production of both H6PDH and 11ß-HSD1 and improved hyperglycaemia and insulin resistance. The reduction of H6PDH and 11ß-HSD1 production by RU486 was accompanied by RU486-induced suppression of hepatic G6pt (also known as Slc37a4) mRNA. Incubation of mouse primary hepatocytes with corticosterone enhanced G6PT and H6PDH production with corresponding activation of 11ß-HSD1 and PEPCK: effects that were blocked by RU486. Knockdown of H6pd by small interfering RNA showed effects comparable with those of RU486 for attenuating the corticosterone-induced H6PDH production and 11ß-HSD1 reductase activity in these intact cells. Addition of the G6PT inhibitor chlorogenic acid to primary hepatocytes suppressed H6PDH production. CONCLUSIONS/INTERPRETATION: These findings suggest that increased hepatic H6PDH and G6PT production contribute to 11ß-HSD1 upregulation of local glucocorticoid action that may be related to the development of type 2 diabetes.


Subject(s)
Carbohydrate Dehydrogenases/metabolism , Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/metabolism , Monosaccharide Transport Proteins/metabolism , 11-beta-Hydroxysteroid Dehydrogenase Type 1/genetics , 11-beta-Hydroxysteroid Dehydrogenase Type 1/metabolism , Animals , Blotting, Western , Carbohydrate Dehydrogenases/genetics , Cells, Cultured , Diabetes Mellitus, Type 2/genetics , Hepatocytes/metabolism , Male , Mice , Mice, Inbred Strains , Monosaccharide Transport Proteins/genetics , Polymerase Chain Reaction
6.
Horm Metab Res ; 42(12): 874-81, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20803415

ABSTRACT

Many Endocrinologists believe that a single determination of eucortisolism or a single demonstration of appropriate suppression to dexamethasone excluded Cushing's syndrome, except in what was previously thought to be the rare patient with episodic or periodic Cushing's syndrome. We hypothesize that episodic Cushing's syndrome is relatively common and a single test assessing hypercortisolism may not be sufficient to accurately rule out or diagnose Cushing's syndrome and retrospectively examined the number of normal and abnormal tests assessing hypercortisolism performed on multiple occasions in 66 patients found to have mild and/or episodic Cushing's syndrome compared to a similar group of 54 patients evaluated for, but determined not to have Cushing's syndrome. We found that 65 of the 66 patients with Cushing's syndrome had at least one normal test of cortisol status and most patients had several normal tests. The probability of having Cushing's syndrome when one test was negative was 92% for 23:00 h salivary cortisol, 88% for 24-h UFC, 86% for 24-h 17OHS, and 54% for nighttime plasma cortisol. These results demonstrated that episodic hypercortisolism is highly prevalent in subjects with mild Cushing's syndrome and no single test was effective in conclusively diagnosing or excluding the condition. Rather, the paradigm for the diagnosis should be a careful history and physical examination and in those patients in whom mild Cushing's syndrome/disease is strongly suspected, multiple tests assessing hypercortisolism should be performed on subsequent occasions, especially when the patient is experiencing signs and symptoms of short-term hypercortisolism.


Subject(s)
Cushing Syndrome/diagnosis , Hydrocortisone/analysis , Adolescent , Adrenocortical Hyperfunction , Adult , Cushing Syndrome/blood , Cushing Syndrome/metabolism , Cushing Syndrome/urine , Female , Humans , Hydrocortisone/blood , Hydrocortisone/urine , Male , Middle Aged , Prevalence , Retrospective Studies , Saliva/chemistry , Saliva/metabolism , Young Adult
7.
Neuroscience ; 167(2): 554-66, 2010 May 05.
Article in English | MEDLINE | ID: mdl-20144693

ABSTRACT

Addictive drugs including opioids activate signal transduction pathways that regulate gene expression in the brain. However, changes in CNS gene expression following morphine exposure are poorly understood. We determined changes in gene expression following short- and long-term morphine treatment in the hypothalamus and pituitary using genome-wide DNA microarray analysis and confirmed those alterations in gene expression by real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis. In the hypothalamus, short-term morphine administration up-regulated (at least twofold) 39 genes and down-regulated six genes. Long-term morphine treatment up-regulated 35 genes and down-regulated 51 genes. In the pituitary, short-term morphine administration up-regulated 110 genes and down-regulated 29 genes. Long-term morphine treatment up-regulated 85 genes and down-regulated 37 pituitary genes. Microarray analysis uncovered several genes involved in food intake (neuropeptide Y, agouti-related protein, and cocaine and amphetamine-regulated transcript) whose expression was strongly altered by morphine exposure in either the hypothalamus or pituitary. Subsequent RT-PCR analysis confirmed similar regulation in expression of these genes in the hypothalamus and pituitary. Finally, we found functional correlation between morphine-induced alterations in food intake and regulation of genes involved in this process. Changes in genes related to food intake may uncover new pathways related to some of the physiological effects of opioids.


Subject(s)
Eating/genetics , Gene Expression Profiling , Morphine/pharmacology , Animals , Body Weight/drug effects , Eating/drug effects , Hypothalamus/drug effects , Hypothalamus/metabolism , Male , Mice , Mice, Inbred C57BL , Morphine Dependence/metabolism , Oligonucleotide Array Sequence Analysis , Pituitary Gland/drug effects , Pituitary Gland/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Substance Withdrawal Syndrome/metabolism , Time Factors
8.
Exp Clin Endocrinol Diabetes ; 118(2): 133-8, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19609841

ABSTRACT

The severity of Cushing's Syndrome (CS) depends on the duration and extent of the exposure to excess glucocorticoids. Current measurements of cortisol in serum, saliva and urine reflect systemic cortisol levels at the time of sample collection, but cannot assess past cortisol levels. Hair cortisol levels may be increased in patients with CS, and, as hair grows about 1 cm/month, measurement of hair cortisol may provide historical information on the development of hypercortisolism. We attempted to measure cortisol in hair in relation to clinical course in six female patients with CS and in 32 healthy volunteers in 1 cm hair sections. Hair cortisol content was measured using a commercially available salivary cortisol immune assay with a protocol modified for use with hair. Hair cortisol levels were higher in patients with CS than in controls, the medians (ranges) were 679 (279-2500) and 116 (26-204) ng/g respectively (P<0.001). Segmental hair analysis provided information for up to 18 months before time of sampling. Hair cortisol concentrations appeared to vary in accordance with the clinical course. Based on these data, we suggest that hair cortisol measurement is a novel method for assessing dynamic systemic cortisol exposure and provides unique historical information on variation in cortisol, and that more research is required to fully understand the utility and limits of this technique.


Subject(s)
Cushing Syndrome/metabolism , Hair/chemistry , Hydrocortisone/analysis , Adult , Body Mass Index , Disease Progression , Female , Humans , Immunoassay , Male , Middle Aged , Reference Values , Severity of Illness Index , Statistics, Nonparametric
9.
Exp Clin Endocrinol Diabetes ; 117(1): 38-43, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18523930

ABSTRACT

The effect of chronic oral opioids on hypothalamus-pituitary-gonadal axis in women, and on bone mineral density (BMD) in men and women is not known. The objective of this cross-sectional study was to determine the effect of long-term oral opioids on gonadal status and BMD in male and female patients with chronic non-cancer pain (CNCP). We included 26 community-dwelling CNCP patients, 12 men and 14 premenopausal women, treated with oral opioids for at least one year. We obtained Visual Analogue Scale for pain score, BMD and plasma LH and FSH in all patients; menstrual history and estradiol in women; free androgen index and total and free testosterone in men. Men were older then women (p<0.05) and had used opioids for a longer period (7.2+/-3.8 and 4.1+/-1.8 years, respectively; p<0.05), but there was no difference in opioid dose or pain score between sexes. The prevalence of hypogonadism was high in men (75%), while only 21% of the women reported oligo- or amenorrhea indicating hypogonadism (P<0.01, between sexes). Osteopenia was found in 50% of men and 21% of women (p=NS). We conclude that in CNCP patients receiving chronic opioid therapy there is a much higher prevalence of hypogonadism in men then in women. This needs to be considered clinical practice.


Subject(s)
Analgesics, Opioid/therapeutic use , Hypogonadism/drug therapy , Pain/drug therapy , Pain/etiology , Adolescent , Adult , Bone Density , Female , Follicle Stimulating Hormone/blood , Humans , Hypogonadism/epidemiology , Hypogonadism/physiopathology , Luteinizing Hormone/blood , Male , Middle Aged , Pain Measurement , Premenopause , Prevalence , Sex Characteristics , Young Adult
10.
Neuroscience ; 156(3): 788-99, 2008 Oct 15.
Article in English | MEDLINE | ID: mdl-18771713

ABSTRACT

Drug addiction is a state of altered brain reward and self-regulation mediated by both neurotransmitter and hormonal systems. Although an organism's internal system attempts to maintain homeostasis when challenged by exogenous opiates and other drugs of abuse, it eventually fails, resulting in the transition from drug use to drug abuse. We propose that the attempted maintenance of hormonal homeostasis is achieved, in part, through alterations in levels of processing enzymes that control the ratio of active hormone to pro-hormone. Two pro-hormone convertases, PC1/3 and PC2 are believed to be responsible for the activation of many neurohormones and expression of these enzymes is dependent on the presence of a cyclic-AMP response element (CRE) in their promoters. Therefore, we studied the effects of short-term (24-h) and long-term (7-day) morphine treatment on the expression of hypothalamic PC1/3 and PC2 and levels of phosphorylated cyclic-AMP-response element binding protein (P-CREB). While short-term morphine exposure down-regulated, long-term morphine exposure up-regulated P-CREB, PC1/3 and PC2 protein levels in the rat hypothalamus as determined by Western blot analysis. Quantitative immunofluorescence studies confirmed these regulatory actions of morphine in the paraventricular and dorsomedial nucleus of the hypothalamus. Specific radioimmunoassays demonstrated that the increase in PC1/3 and PC2 levels following long-term morphine led to increased TRH biosynthesis as evidence by increased TRH/5.4 kDa C-terminal proTRH-derived peptide ratios in the median eminence. Promoter activity experiments in rat somatomammotrope GH3 cells containing the mu-opioid receptor demonstrated that the CRE(s) in the promoter of PC1/3 and PC2 is required for morphine-induced regulation of PC1/3 and PC2. Our data suggest that the regulation of the prohormone processing system by morphine may lead to alterations in the levels of multiple bioactive hormones and may be a compensatory mechanism whereby the organism tries to restore its homeostatic hormonal milieu. The down-regulation of PC1/3, PC2 and P-CREB by short-term morphine and up-regulation by long-term morphine treatment may be a signal mediating the switch from drug use to drug abuse.


Subject(s)
Cyclic AMP Response Element-Binding Protein/metabolism , Gene Expression Regulation/drug effects , Morphine/pharmacology , Narcotics/pharmacology , Proprotein Convertase 1/metabolism , Proprotein Convertase 2/metabolism , Animals , Behavior, Animal , Body Weight/drug effects , Brain/drug effects , Brain/metabolism , Brain/pathology , Cell Line, Transformed , Male , Morphine/adverse effects , Narcotics/adverse effects , Pain Measurement , Proprotein Convertase 1/genetics , Proprotein Convertase 2/genetics , Radioimmunoassay/methods , Rats , Rats, Sprague-Dawley , Reaction Time/drug effects , Substance Withdrawal Syndrome/drug therapy , Substance Withdrawal Syndrome/physiopathology , Thyrotropin-Releasing Hormone/metabolism , Time Factors , Transfection
11.
Horm Metab Res ; 40(11): 813-8, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18819057

ABSTRACT

Women with Cushing's syndrome (CS) and polycystic ovarian syndrome (PCOS) may present with similar symptoms. Subjects with mild CS lack clinical stigmata of classical CS and often have normal laboratory tests measuring hypercortisolism. Thus, distinguishing mild CS from PCOS may be difficult. We hypothesized that either total testosterone (TT) or bioavailable testosterone (BT) levels or the calculation of the free androgen index (FAI) would be low in patients with mild CS and elevated in patients with PCOS, and could help differentiate the two conditions. TT, BT, and FAI were measured in a group of 20 patients of reproductive age with mild CS and 20 PCOS patients matched for age and BMI. We used receiver operator characteristic (ROC) curves to assess the sensitivity and specificity of these measurements for the diagnosis of CS. TT (p<0.0001), BT (p=0.02), and FAI (p=0.003) were significantly elevated in PCOS patients compared to mild CS patients. Sex hormone-binding globulin was similar in both groups. The optimal cut-point for TT was 1.39 nmol/L, yielding a sensitivity of 95% and a specificity of 70%. The cut-point for BT was 0.24 nmol/L, resulting in a sensitivity of 75% and a specificity of 80%. The cut-point for FAI was 5.7, with a sensitivity of 88% and a specificity of 60%. We conclude that TT levels may be useful to discriminate between mild CS and PCOS. In patients with signs and symptoms consistent with CS and PCOS, a TT level of <1.39 nmol/L warrants a workup for CS.


Subject(s)
Cushing Syndrome/diagnosis , Polycystic Ovary Syndrome/diagnosis , Testosterone/blood , Adult , Androgens/blood , Biological Availability , Diagnosis, Differential , Female , Hirsutism , Humans , Oligomenorrhea , ROC Curve , Sensitivity and Specificity , Sex Hormone-Binding Globulin/metabolism
12.
Horm Metab Res ; 39(6): 451-6, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17578763

ABSTRACT

AIM: The diagnosis of mild or episodic Cushing's syndrome is difficult. The standard tests include 24-hour urinary free cortisol (UFC), night-time blood, or salivary cortisol measurements, and dexamethasone suppression tests. Imaging studies of the pituitary have not been recommended as part of the initial workup (only to help distinguish pituitary Cushing's disease from the ectopic ACTH syndrome) because of poor sensitivity and specificity. With the development of dynamic pituitary MRI which uses multiple coronal dynamic sequences following gadolinium intravenous contrast, we hypothesized that the sensitivity and specificity would be increased and MRI would provide useful information for the initial diagnosis of Cushing's syndrome. METHODS: This was a retrospective chart review examining charts from 87 consecutive patients who were evaluated for Cushing's syndrome in a tertiary Endocrinology clinic over a one-year period. Most patients had mild and/or episodic hypercortisolism. Of these patients, 24 eventually were diagnosed with pituitary Cushing's syndrome by biochemical testing (24-h UFC and urinary 17-hydroxycorticosteroids, 11 PM salivary cortisol measurements, evening plasma cortisol), and 22 had the diagnosis of Cushing's syndrome excluded. Dynamic pituitary MRI (1.5 Tesla) was performed on all patients. The reader of the MRI was blind to the diagnosis. RESULTS: Twenty-three of 24 patients had a MRI consistent with a pituitary lesion (21 with a microadenoma, two with pituitary asymmetry). In contrast, only 3 of 20 patients (2 patient did not have MRIs) in the Cushing's excluded group had a pituitary lesion on dynamic MRI. Dynamic pituitary MRI had the highest sensitivity and negative predictive value of any testing modalities and its specificity and positive predictive value were similar to that of other tests. CONCLUSION: We conclude that almost all patients in this series with Cushing's syndrome have a lesion on dynamic pituitary MRI, a rate much higher than the 50-60% rate reported for non-dynamic MRIs. The false positive rate of 16% in our group of Cushing's excluded patients is similar to the literature value of 10% seen in normal volunteers and is acceptable since MRI is not used solely as a determinant for the diagnosis. While a negative MRI will miss those patients with adrenal or ectopic Cushing's syndrome, those patients can usually be diagnosed by other testing. Thus this preliminary study implies that dynamic pituitary MRI adds valuable information to assist in the diagnosis of Cushing's syndrome and should be ordered as part of the initial workup.


Subject(s)
Cushing Syndrome/diagnosis , Magnetic Resonance Imaging/methods , Pituitary Gland/pathology , Adolescent , Adult , Female , Humans , Middle Aged , Retrospective Studies , Sensitivity and Specificity
13.
Exp Clin Endocrinol Diabetes ; 114(7): 356-60, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16915537

ABSTRACT

The overnight one-mg dexamethasone suppression test has been used for many years to screen for Cushing's syndrome. This test has usually been evaluated in controls versus patients with severe hypercortisolism. Under these conditions, the overnight dexamethasone suppression test has been reported to have high sensitivity and specificity. The objective of this study was to determine the sensitivity of the one mg overnight dexamethasone suppression test in patients with mild and/or periodic Cushing's syndrome. Therefore, an overnight dexamethasone suppression test was performed in 17 consecutive patients presenting to an endocrinology clinic with signs and symptoms of hypercortisolemia who were later proven to have Cushing's syndrome. The majority of patients were found to have both mild and periodic hypercortisolism. One mg of dexamethasone was given at midnight and a plasma cortisol was measured by radioimmunoassay at 08:00 the following morning. Using a cut-off for a morning cortisol following overnight dexamethasone of > 5 microg/dL, only three of 17 patients failed to suppress to a value less than this cut-off (sensitivity 18 %). A cut-off of > 2 microg/dL gave similar sensitivity. Even with a stringent cut-off point of > 1.8 microg/dL, only seven of 17 patients failed to suppress to a value less than this cut-off point (sensitivity of 41 %). These results demonstrate that the great majority of patients with mild and/or periodic Cushing's syndrome suppress to overnight dexamethasone. Since patients with mild and/or periodic Cushing's syndrome are the patients in whom the identification of hypercortisolism is difficult, our results from this relatively small study suggest that this test should no longer be used to exclude these patients from further workup for Cushing's syndrome.


Subject(s)
Cushing Syndrome/diagnosis , Dexamethasone , Hydrocortisone/blood , Adolescent , Adult , Body Mass Index , Humans , Middle Aged
14.
J Mol Endocrinol ; 33(1): 21-33, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15291740

ABSTRACT

Most pro-neuropeptides are processed by the prohormone convertases, PC1 and PC2. We previously reported that changes in thyroid status altered anterior pituitary PC1 mRNA and this regulation was due to triiodothyronine (T(3))-dependent interaction of thyroid hormone receptor (TR) with negative thyroid hormone response elements (nTREs) contained in a large region of the human PC1 promoter. In this study, we demonstrated that hypothyroidism stimulated, while hyperthyroidism suppressed, PC1 mRNA levels in rat hypothalamus and cerebral cortex, but not in hippocampus. In situ hybridization was used to confirm real-time PCR changes and localize the regulation within the hypothalamus and cortex. Using a human PC1 (hPC1) promoter construct (with and without deletions in two regions that each contain a negative TRE) transiently transfected into GH3 cells, we found that T(3) negatively regulated hPC1 promoter activity, and this regulation required both of these two regions. Electrophoretic mobility shift assays (EMSAs) using purified thyroid hormone receptor alpha1 (TRalpha1) and retinoid X receptor beta (RXRbeta) proteins demonstrated that RXR and TRalpha both bound the PC1 promoter. Addition of TRalpha1/RXRbeta to the wild-type PC1 probe demonstrated binding as both homodimers and a heterodimer. EMSAs with oligonucleotides containing deletion mutations of the putative nTREs demonstrated that the proximal nTRE binds more strongly to TR and RXR than the distal nTRE, but that both regions exhibit specific binding. We conclude that there are multiple novel TRE-like sequences in the hPC1 promoter and that these regions act in a unique manner to facilitate the negative effect of thyroid hormone on PC1.


Subject(s)
Brain/enzymology , Proprotein Convertase 1/metabolism , Thyroid Hormones/physiology , Animals , Base Sequence , Cell Line , Electrophoretic Mobility Shift Assay , Humans , In Situ Hybridization , In Vitro Techniques , Male , Promoter Regions, Genetic , Proprotein Convertase 1/genetics , Rats , Reverse Transcriptase Polymerase Chain Reaction
15.
Regul Pept ; 102(2-3): 135-45, 2001 Dec 15.
Article in English | MEDLINE | ID: mdl-11730986

ABSTRACT

Organisms respond to infection in a complex manner involving bidirectional interactions between the neuroendocrine and immune systems. Many of the bioactive endocrine/immune factors are synthesized in a precursor form and are expected to be activated by prohormone convertases (PCs). Since patients with both type 1 and type 2 diabetes have an increased incidence and severity of infections, we hypothesized that in a condition of hyperglycemia, these processing enzymes would be activated in an immune tissue, the spleen. To test this hypothesis, we treated rats with intraperitoneal streptozotocin (STZ) (50 mg/kg/day) daily for 5 days and measured splenic PC1 and PC2 mRNA by ribonuclease protection assay. We found that PC1 mRNA was increased 6.0+/-0.02-fold (P<0.05) and PC2 mRNA was increased 1.80+/-0.01-fold (P<0.005) in the spleen of rats that received STZ compared to rats that received vehicle. Western blot indicated that the 75-kDa form of PC1 was the only form of PC1 present in the spleen and that this form increased with STZ treatment. Immunohistochemistry revealed that PC1 was found in both the white pulp (T-lymphocytes) and red pulp (monocytes and macrophages) and that its increase in immunoreactivity occurred primarily in the white pulp. PC2 and pro-opiomelanocortin (POMC, a possible splenic substrate for PC1/PC2) immunoreactivity was found predominantly in the red pulp. STZ induced an increase in splenic PC1 and POMC, but not PC2 protein levels. We conclude that in the STZ model of diabetes, splenic PCs are induced, which could lead to an increased activation of many immune-derived hormones. We speculate that this up-regulation of prohormone converting enzymes may be related to the increased infections seen in patients with both type 1 and type 2 diabetes.


Subject(s)
Aspartic Acid Endopeptidases/metabolism , Diabetes Mellitus, Experimental/enzymology , Subtilisins/metabolism , Up-Regulation , Animals , Anti-Bacterial Agents/pharmacology , Aspartic Acid Endopeptidases/genetics , Blotting, Western , Diabetes Mellitus, Experimental/metabolism , Disease Models, Animal , Hypothalamus/drug effects , Hypothalamus/enzymology , Hypothalamus/metabolism , Immunohistochemistry , Pituitary Gland/drug effects , Pituitary Gland/enzymology , Pituitary Gland/metabolism , Pro-Opiomelanocortin/metabolism , Proprotein Convertase 2 , Proprotein Convertases , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Ribonucleases/metabolism , Spleen/drug effects , Spleen/enzymology , Spleen/metabolism , Streptozocin/pharmacology , Subtilisins/genetics , Up-Regulation/drug effects
18.
Am J Physiol Endocrinol Metab ; 280(1): E160-70, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11120670

ABSTRACT

The prohormone convertases (PCs) PC1 and PC2 are key enzymes capable of processing a variety of prohormones to their bioactive forms. In this study, we demonstrated that 6-n-propyl-2-thiouracil (PTU)-induced hypothyroidism stimulated, whereas triido-L-thyronine (T(3))-induced hyperthyroidism suppressed, PC1 mRNA levels in the rat anterior pituitary. Using 5' deletions of the human PC1 (hPC1) promoter transiently transfected into GH3 (a somatotroph cell line) cells, we found that T(3) negatively regulated hPC1 promoter activity and that this regulation required the region from -82 to +19 bp relative to the transcription start site. Electrophoretic mobility shift assays (EMSAs) using purified thyroid hormone receptor-alpha1 (TR alpha 1) and retinoid X receptor-beta (RXRbeta) proteins and GH3 nuclear extracts demonstrated that the region from -10 to +19 bp of the hPC1 promoter bound TR alpha 1 as both a monomer and a homodimer and bound TR alpha 1/RXR beta as a heterodimer and multimer. EMSAs with oligonucleotides containing point mutations of the putative negative thyroid response elements (TREs) exhibited diminished homodimer and loss of multimer binding. We conclude that there are multiple novel TRE-like sequences in the hPC1 promoter located from -10 to +19 bp.


Subject(s)
Aspartic Acid Endopeptidases/genetics , Aspartic Acid Endopeptidases/metabolism , Hypothyroidism/metabolism , Triiodothyronine/metabolism , Uracil/analogs & derivatives , Alitretinoin , Animals , Antineoplastic Agents/pharmacology , Cells, Cultured , Gene Deletion , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Enzymologic/physiology , Genes, Reporter , Hypothyroidism/chemically induced , Luciferases/genetics , Male , Mutagenesis, Insertional/physiology , Oligonucleotides/genetics , Oligonucleotides/metabolism , Peptide Fragments/metabolism , Pituitary Gland, Anterior/metabolism , Promoter Regions, Genetic/physiology , Proprotein Convertases , Protein Processing, Post-Translational/drug effects , Protein Processing, Post-Translational/physiology , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Retinoic Acid/metabolism , Retinoid X Receptors , Transcription Factors/metabolism , Tretinoin/pharmacology
19.
J Clin Endocrinol Metab ; 85(11): 4201-6, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11095454

ABSTRACT

There is a well described temporal relation between hormonal secretion and sleep phase, with hormones of the hypothalamic-pituitary-adrenal (HPA) axis possibly playing a role in determining entry into and duration of different sleep stages. In this study sleep features were studied in primary Addison's patients with undetectable levels of cortisol treated in a double blind, randomized, cross-over fashion with either hydrocortisone or placebo supplementation. We found that REM latency was significantly decreased in Addison's patients when receiving hydrocortisone at bedtime, whereas REM sleep time was increased. There was a trend toward an increase in the percentage of time in REM sleep and the number of REM sleep episodes. Waking time after sleep onset was increased, whereas no differences were observed between the two conditions when total sleep time or specific non-REM sleep parameters were evaluated. Our results suggest that in Addison's patients, cortisol plays a positive, permissive role in REM sleep regulation and may help to consolidate sleep. These effects may be mediated either directly by the central effects of glucocorticoids and/or indirectly through CRH and/or ACTH.


Subject(s)
Addison Disease/drug therapy , Addison Disease/physiopathology , Hormone Replacement Therapy , Hydrocortisone/therapeutic use , Sleep, REM/physiology , Sleep/physiology , Adrenocorticotropic Hormone/blood , Adult , Circadian Rhythm , Cross-Over Studies , Delta Sleep-Inducing Peptide/blood , Double-Blind Method , Female , Human Growth Hormone/blood , Humans , Hydrocortisone/blood , Male , Middle Aged
20.
Endocrinology ; 141(9): 3256-66, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10965896

ABSTRACT

The majority of prohormones are cleaved at paired basic residues to generate bioactive hormones by prohormone convertases (PCs). As PC1 and PC2, two neuroendocrine-specific PCs, appear to be the key enzymes capable of processing a variety of prohormones, alterations of PC2 and/or PC1 levels will probably have a profound effect on hormonal homeostasis. We investigated the regulation of PC2 messenger RNA (mRNA) by thyroid hormone using GH3 cells to demonstrate that T3 negatively regulated PC2 mRNA levels in a dose- and time-dependent fashion. Functional analysis of progressive 5'-deletions of the human (h) PC2 promoter luciferase constructs in GH3 cells demonstrated that the regulation probably occurs at the transcriptional level, and that putative negative thyroid hormone response elements were located within the region from -44 to + 137 bp relative to the transcriptional start site. Transient transfections in JEG-3 cells and COS-1 cells showed that the suppressive effect of T3 was equally mediated by the thyroid hormone receptor (TR) isoforms TRalpha1 and TRbeta1. Electrophoretic mobility shift assays using purified TRal and retinoid X receptor-beta protein as well as GH3 nuclear extracts showed that regions from +51 to +71 bp and from +118 to +137 bp of the hPC2 promoter bind to TRalpha1 as both a monomer and a homodimer and with TRalpha1/retinoid X receptor-beta as a heterodimer. Finally, the in vivo regulation of pituitary PC2 mRNA by thyroid status was demonstrated in rats. These results demonstrate that T3 negatively regulates PC2 expression at the transcriptional level and that functional negative thyroid hormone response elements exist in the hPC2 promoter. We postulate that the alterations of PC2 activity may mediate some of the pathophysiological consequences of hypo- or hyperthyroidism.


Subject(s)
Promoter Regions, Genetic/genetics , Receptors, Thyroid Hormone/genetics , Subtilisins/genetics , Animals , Antithyroid Agents/pharmacology , Blotting, Northern , Cell Line , Electrophoresis , Gene Deletion , Growth Hormone/biosynthesis , Growth Hormone/genetics , Humans , Isotretinoin/pharmacology , Luciferases/genetics , Male , Plasmids/genetics , Proprotein Convertase 2 , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Triiodothyronine/pharmacology , Triiodothyronine/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...